SAN DIEGO, Dec. 12 /PRNewswire-FirstCall/ -- Metabasis Therapeutics , announced today that the Company will host its first Investor Research & Development Meeting on Thursday, December 14, 2006 at the Warwick New York Hotel in New York, NY. The event is scheduled to run from approximately 8:00 a.m. - 11:00 a.m. Eastern Time. Dr. Paul Laikind, president and CEO, is expected to provide a general business overview and Dr. Mark Erion, executive vice president of research and development and CSO, is expected to present on the Company's product candidates in clinical and pre-clinical development.
To access the live audio broadcast and the subsequent archived audio recording of the presentation, please log onto the Company's website at www.mbasis.com under the "Investors" section. Please connect to Metabasis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. The audio recording will be archived there for 30 days following the live presentation.
About Metabasis (www.mbasis.com):
Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread and costly chronic diseases involving pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include major metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Metabasis TherapeuticsCONTACT: Constance Bienfait, Vice President of Investor Relations &Corporate Communications of Metabasis Therapeutics, Inc., +1-858-622-5575
Web site: http://www.mbasis.com/
